The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs

Detalhes bibliográficos
Autor(a) principal: Castel-Branco, M. M.
Data de Publicação: 2009
Outros Autores: Alves, G. L., Figueiredo, I. V., Falcão, Amílcar, Caramona, M. M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/11809
https://doi.org/10.1358/mf.2009.31.2.1338414
Resumo: The choice of appropriate animal models for the initial in vivo testing of potential anticonvulsant compounds is one of the most important steps in the successful search for new antiepileptic drugs. The purpose of this paper is to describe the most important aspects to take into account when performing the maximal electroshock seizure (MES) test in the routine laboratory screening of new antiepileptics: the conventional and threshold MES test experimental procedures, the factors affecting experimental data (laboratory conditions, administration vehicles and drug formulations, time after drug administration, and stimulus duration and site of stimulation) and the assessment of anticonvulsant activity are discussed.
id RCAP_d7ce560a8ff63cc243f90055d5d9a262
oai_identifier_str oai:estudogeral.uc.pt:10316/11809
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugsAntiepilépticosTestes in vivoModelos de convulsõesElectrochoqueThe choice of appropriate animal models for the initial in vivo testing of potential anticonvulsant compounds is one of the most important steps in the successful search for new antiepileptic drugs. The purpose of this paper is to describe the most important aspects to take into account when performing the maximal electroshock seizure (MES) test in the routine laboratory screening of new antiepileptics: the conventional and threshold MES test experimental procedures, the factors affecting experimental data (laboratory conditions, administration vehicles and drug formulations, time after drug administration, and stimulus duration and site of stimulation) and the assessment of anticonvulsant activity are discussed.3910-3178-31BA | MARIA MARGARIDA COUTINHO DE SEABRA CASTEL-BRANCO CAETANOinfo:eu-repo/semantics/publishedVersionProus Scientific2009-03info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/11809http://hdl.handle.net/10316/11809https://doi.org/10.1358/mf.2009.31.2.1338414engMethods Find Exp Clin Pharmacol. 31:1 (2009) 101-106.cv-prod-143882Castel-Branco, M. M.Alves, G. L.Figueiredo, I. V.Falcão, AmílcarCaramona, M. M.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-08-29T14:20:37Zoai:estudogeral.uc.pt:10316/11809Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:47:28.414994Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs
title The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs
spellingShingle The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs
Castel-Branco, M. M.
Antiepilépticos
Testes in vivo
Modelos de convulsões
Electrochoque
title_short The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs
title_full The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs
title_fullStr The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs
title_full_unstemmed The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs
title_sort The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs
author Castel-Branco, M. M.
author_facet Castel-Branco, M. M.
Alves, G. L.
Figueiredo, I. V.
Falcão, Amílcar
Caramona, M. M.
author_role author
author2 Alves, G. L.
Figueiredo, I. V.
Falcão, Amílcar
Caramona, M. M.
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Castel-Branco, M. M.
Alves, G. L.
Figueiredo, I. V.
Falcão, Amílcar
Caramona, M. M.
dc.subject.por.fl_str_mv Antiepilépticos
Testes in vivo
Modelos de convulsões
Electrochoque
topic Antiepilépticos
Testes in vivo
Modelos de convulsões
Electrochoque
description The choice of appropriate animal models for the initial in vivo testing of potential anticonvulsant compounds is one of the most important steps in the successful search for new antiepileptic drugs. The purpose of this paper is to describe the most important aspects to take into account when performing the maximal electroshock seizure (MES) test in the routine laboratory screening of new antiepileptics: the conventional and threshold MES test experimental procedures, the factors affecting experimental data (laboratory conditions, administration vehicles and drug formulations, time after drug administration, and stimulus duration and site of stimulation) and the assessment of anticonvulsant activity are discussed.
publishDate 2009
dc.date.none.fl_str_mv 2009-03
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/11809
http://hdl.handle.net/10316/11809
https://doi.org/10.1358/mf.2009.31.2.1338414
url http://hdl.handle.net/10316/11809
https://doi.org/10.1358/mf.2009.31.2.1338414
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Methods Find Exp Clin Pharmacol. 31:1 (2009) 101-106.
cv-prod-143882
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Prous Scientific
publisher.none.fl_str_mv Prous Scientific
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1817550269171367936